164 related articles for article (PubMed ID: 10903942)
21. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery.
Liu Y; Sun J; Cao W; Yang J; Lian H; Li X; Sun Y; Wang Y; Wang S; He Z
Int J Pharm; 2011 Dec; 421(1):160-9. PubMed ID: 21945183
[TBL] [Abstract][Full Text] [Related]
22. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.
Ginj M; Chen J; Walter MA; Eltschinger V; Reubi JC; Maecke HR
Clin Cancer Res; 2005 Feb; 11(3):1136-45. PubMed ID: 15709181
[TBL] [Abstract][Full Text] [Related]
23. The taxol pharmacophore and the T-taxol bridging principle.
Kingston DG; Bane S; Snyder JP
Cell Cycle; 2005 Feb; 4(2):279-89. PubMed ID: 15611640
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced anti-angiogenic and anti-glioma therapy.
Banerjee I; De K; Mukherjee D; Dey G; Chattopadhyay S; Mukherjee M; Mandal M; Bandyopadhyay AK; Gupta A; Ganguly S; Misra M
Acta Biomater; 2016 Jul; 38():69-81. PubMed ID: 27109765
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and beta-lactamase-mediated activation of a cephalosporin-taxol prodrug.
Rodrigues ML; Carter P; Wirth C; Mullins S; Lee A; Blackburn BK
Chem Biol; 1995 Apr; 2(4):223-7. PubMed ID: 9383424
[TBL] [Abstract][Full Text] [Related]
26. Identification of somatostatin receptors using labeled PEGylated octreotide, as an active internalization.
Abdellatif AAH
Drug Dev Ind Pharm; 2019 Oct; 45(10):1707-1715. PubMed ID: 31418304
[TBL] [Abstract][Full Text] [Related]
27. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q
Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191
[TBL] [Abstract][Full Text] [Related]
28. Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells.
Kojic LD; Wiseman SM; Ghaidi F; Joshi B; Nedev H; Saragovi HU; Nabi IR
PLoS One; 2008; 3(10):e3597. PubMed ID: 18974847
[TBL] [Abstract][Full Text] [Related]
29. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
Koppan M; Nagy A; Schally AV; Arencibia JM; Plonowski A; Halmos G
Cancer Res; 1998 Sep; 58(18):4132-7. PubMed ID: 9751625
[TBL] [Abstract][Full Text] [Related]
30. In vivo cellular distribution and endocytosis of the somatostatin receptor-ligand complex.
Lukinius A; Ohrvall U; Westlin JE; Oberg K; Tiensuu Janson E
Acta Oncol; 1999; 38(3):383-7. PubMed ID: 10380832
[TBL] [Abstract][Full Text] [Related]
31. Intracellular degradation of somatostatin-14 following somatostatin-receptor3-mediated endocytosis in rat insulinoma cells.
Roosterman D; Brune NE; Kreuzer OJ; Feld M; Pauser S; Zarse K; Steinhoff M; Meyerhof W
FEBS J; 2008 Oct; 275(19):4728-39. PubMed ID: 18702662
[TBL] [Abstract][Full Text] [Related]
32. Octreotide stimulates somatostatin receptor-induced apoptosis of SW480 colon cancer cells by activation of glycogen synthase kinase-3β, A Wnt/β-catenin pathway modulator.
Wang S; Bao Z; Liang QM; Long JW; Xiao ZS; Jiang ZJ; Liu B; Yang J; Long ZX
Hepatogastroenterology; 2013 Oct; 60(127):1639-46. PubMed ID: 24634935
[TBL] [Abstract][Full Text] [Related]
33. Octreotide-conjugated PAMAM for targeted delivery to somatostatin receptors over-expressed tumor cells.
Peng J; Qi X; Chen Y; Ma N; Zhang Z; Xing J; Zhu X; Li Z; Wu Z
J Drug Target; 2014 Jun; 22(5):428-38. PubMed ID: 24437350
[TBL] [Abstract][Full Text] [Related]
34. Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines.
Wang Y; Yu L; Han L; Sha X; Fang X
Int J Pharm; 2007 Jun; 337(1-2):63-73. PubMed ID: 17289311
[TBL] [Abstract][Full Text] [Related]
35. Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells.
Amaya C; Luo S; Baigorri J; Baucells R; Smith ER; Xu XX
BMC Cancer; 2021 Sep; 21(1):981. PubMed ID: 34470602
[TBL] [Abstract][Full Text] [Related]
36. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition.
Díaz JF; Andreu JM
Biochemistry; 1993 Mar; 32(11):2747-55. PubMed ID: 8096151
[TBL] [Abstract][Full Text] [Related]
37. PEG-derivatized octacosanol as micellar carrier for paclitaxel delivery.
Chu B; Qu Y; Huang Y; Zhang L; Chen X; Long C; He Y; Ou C; Qian Z
Int J Pharm; 2016 Mar; 500(1-2):345-59. PubMed ID: 26794876
[TBL] [Abstract][Full Text] [Related]
38. Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo.
Liu T; Jia T; Yuan X; Liu C; Sun J; Ni Z; Xu J; Wang X; Yuan Y
Int J Nanomedicine; 2016; 11():2235-50. PubMed ID: 27284243
[TBL] [Abstract][Full Text] [Related]
39. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway.
Woods CM; Zhu J; McQueney PA; Bollag D; Lazarides E
Mol Med; 1995 Jul; 1(5):506-26. PubMed ID: 8529117
[TBL] [Abstract][Full Text] [Related]
40. Structural determinants of agonist-selective signaling at the sst(2A) somatostatin receptor.
Nagel F; Doll C; Pöll F; Kliewer A; Schröder H; Schulz S
Mol Endocrinol; 2011 May; 25(5):859-66. PubMed ID: 21330405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
